FDA Approves Expanded Age Indication for RSV Vaccine Arexvy
The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased risk.
Source: ajmc.com
Annr Falsey News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Annr Falsey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Annr Falsey Today - Breaking & Trending Today
GSK : DO NOT COURIER US FDA approves expanded age indication for GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1 Clinical development programme continues to...
Source: marketscreener.com
US FDA Approves Expanded Age Indication for GSK's AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk Seite 1
08.06.2024 - GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through ... Seite 1
Source: wallstreet-online.de
US FDA Approves Expanded Age Indication for GSK's AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1 Clinical development program continues to evaluate safety and immunogenicity...
Source: marketscreener.com
Beyond Babies, RSV Infections Put Older People at Risk Too
RSV in older Americans 'remains under-recognized by both physicians and especially the public,' says a University of Rochester School of Medicine professor who specializes in respiratory viral infections.
Source: medscape.com